INVESTORS

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Achillion Announces Strengthening of Management Team
- Mr. Joseph Truitt promoted to Chief Operating Officer -  - Dr. Avner Ingerman joins as Head of Ophthalmology - NEW HAVEN, Conn., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that Executive Vice President Joseph Truitt has been promoted to Chief
View HTML
Toggle Summary Achillion Announces Termination of Worldwide Collaboration for Hepatitis C With Janssen
- Conference call to be held today at 9:00 a.m. ET- NEW HAVEN, Conn., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that on Saturday, September 9, 2017, it received notice of termination of the worldwide license and collaboration arrangement on
View HTML
Toggle Summary Achillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor
- Interim results demonstrate ability of ACH-4471 to reduce LDH and improve hemoglobin and fatigue scores in patients with untreated PNH - - Global program expansion planned in PNH, C3G and IC-MPGN - - Conference call scheduled for today at 4:05 p.m. ET - NEW HAVEN, Conn., Aug.
View HTML
Toggle Summary Achillion to Host Second Quarter 2017 Results Conference Call on August 8, 2017
- Conference call and live webcast will begin at 4:05 p.m. ET on August 8, 2017 -
View HTML
Toggle Summary Achillion Pharmaceutials Announces Key Promotion and Discovery Organization Change
NEW HAVEN, Conn., July 10, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), the leader in complement alternative pathway therapeutics, today announced that Mingjun Huang, Ph.D., is being promoted to Senior Vice President and Head of Research. With this promotion, Dr.
View HTML
Toggle Summary Achillion to Present at the 2017 JMP Securities Life Sciences Conference
NEW HAVEN, Conn., June 15, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will participate in a fireside chat at the JMP Securities Life Sciences Conference on Tuesday, June 20,
View HTML
Toggle Summary Achillion to Present at the Jefferies 2017 Global Healthcare Conference
NEW HAVEN, Conn., June 05, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the Achillion management team will present a corporate overview at the Jefferies 2017 Global Healthcare Conference on Tuesday, June 6, 2017, at 4:30 p.m.
View HTML
Toggle Summary Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs
Robust balance sheet to support planned Phase 2 clinical development program for ACH-4471, Achillion's first small molecule factor D inhibitor, for the potential treatment of PNH and C3G
View HTML
Toggle Summary Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference
NEW HAVEN, Conn., May 02, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 42 nd Annual Health Care Conference on Thursday,
View HTML
Toggle Summary Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178
Ongoing Janssen global Phase 2 program with JNJ-4178, (odalasvir, AL-335, and simeprevir) focused on treatment durations of six and eight weeks for HCV genotype 1, 2, 4, 5, and 6 patients
View HTML